Cell-type specific interferon stimulated gene staining in liver underlies response to interferon therapy in chronic hbv infected patients

Digestive Diseases and Sciences

Volumn 57, Issue 9, 2012, Pages 2355-2361

  Zhu, Yanling ^a   Qin, Bo ^a   Xiao, Chunyan ^a   Lu, Xi ^a   Chen, Limin ^b,c  

^a THE FIRST AFFILIATED HOSPITAL OF CHONGQING MEDICAL UNIVERSITY   (China)

^b INSTITUTE OF BLOOD TRANSFUSION   (China)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

Chronic hepatitis B (CHB); IFN ; Immunohistochemistry; ISG15; MxA; Treatment response

Indexed keywords

ALPHA2A INTERFERON; INTERFERON; MYXOVIRUS RESISTANCE PROTEIN A;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; HEPATITIS B; HEPATITIS VIRUS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTERFERON STIMULATED GENE 15; LIVER CELL; MACROPHAGE; MALE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADOLESCENT; ADULT; CYTOKINES; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GTP-BINDING PROTEINS; HEPATITIS B, CHRONIC; HUMANS; IMMUNOHISTOCHEMISTRY; INTERFERON-ALPHA; LIVER; MALE; MIDDLE AGED; UBIQUITINS;

EID: 84866388226     PISSN: 01632116     EISSN: 15732568     Source Type: Journal    
DOI: 10.1007/s10620-012-2169-5     Document Type: Article

References (30)

1. Huang LM, Lu CY, Chen DS. Hepatitis B virus infection, its sequelae, and prevention by vaccination. Curr Opin Immunol. 2011;23:237-243.
2. Hadziyannis SJ, Papatheodoridis GV, Vassilopoulos D. Treatment of HBeAg-negative chronic hepatitis B. Semin Liver Dis. 2003;23:81-88. (Pubitemid 36254665)
3. Heathcote J. Treatment of HBe antigen-positive chronic hepatitis B. Semin Liver Dis. 2003;23:69-80.
4. Kao JH. Appropriate use of interferon for treatment of chronic hepatitis B. Hepatol Res. 2007;37:S47-S54. (Pubitemid 47086516)
5. Xiao C, Qin B, Chen L, Liu H, Zhu Y, Lu X. Preactivation of the interferon signalling in liver is correlated with nonresponse to interferon alpha therapy in patients chronically infected with hepatitis B virus. J Viral Hepat. 2012;19:e1-e10.
6. Liaw YF, Leung N, Kao JH, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hep Intl. 2008;2:263-283.
7. Borgogna C, Toniutto P, Smirne C, et al. Expression of the interferon-inducible proteins MxA and IFI16 in liver allografts. Histopathology. 2009;54:837-846.
8. MacQuillan GC, de Boer WB, Allan JE, Platten MA, Reed WD, Jeffrey GP. Hepatocellular MxA protein expression supports the differentiation of recurrent hepatitis C disease from acute cellular rejection after liver transplantation. Clin Transpl. 2010;24:252-258.
9. MacQuillan GC, de Boer WB, Platten MA, et al. Intrahepatic MxA and PKR protein expression in chronic hepatitis C virus infection. J Med Virol. 2002;68:197-205.
10. Haas AL, Ahrens P, Bright P, Ankel H. Interferon induces a 15-kilodalton protein exhibiting marked homology to ubiquitin. J Biol Chem. 1987;262:11315.
11. Brunt EM. Pathology of hepatic iron overload. Semin Liver Dis. 2005;25:392-401. (Pubitemid 41741256)
12. Zhao H, Kurbanov F, Wan MB, et al. Genotype B and younger patient age associated with better response to low-dose therapy: a trial with pegylated/nonpegylated interferon-α-2b for hepatitis B e antigenpositive patients with chronic hepatitis B in China. Clin Infect Dis. 2007;44:541. (Pubitemid 46233256)
13. Chen L, Borozan I, Feld J, et al. Hepatic gene expression discriminates responders and nonresponders in treatment of chronic hepatitis C viral infection. Gastroenterology. 2005;128:1437-1444. (Pubitemid 40712193)
14. Chen L, Borozan I, Sun J, et al. Cell-type specific gene expression signature in liver underlies response to interferon therapy in chronic hepatitis C infection. Gastroenterology. 2010;138:1123-1133.
15. Haller O, Staeheli P, Kochs G. Interferon-induced Mx proteins in antiviral host defense. Biochimie. 2007;89:812-818. (Pubitemid 47001645)
16. Tangkijvanich P, Komolmit P, Mahachai V, Sa-nguanmoo P, Theamboonlers A, Poovorawan Y. Low pretreatment serum HBsAg level and viral mutations as predictors of response to PEG-interferon alpha-2b therapy in chronic hepatitis B. J Clin Virol. 2009;46:117-123.
17. Krejčová D, Procházková J, Kubala L, Pacherník J. Modulation of cell proliferation and differentiation of human lung carcinoma cells by the interferon-alpha. Gen Physiol Biophys. 2009;28:294-301.
18. Yu Z, Wang Z, Chen J, et al. GTPase activity is not essential for the interferon-inducible MxA protein to inhibit the replication of hepatitis B virus. Arch Virol. 2008;153:1677-1684.
19. Rang A, Bruns M, Heise T, Will H. Antiviral activity of interferon-alpha against hepatitis B virus can be studied in non-hepatic cells and Is independent of MxA. J Biol Chem. 2002;277:7645-7647. (Pubitemid 34968208)
20. Frese M, Pietschmann T, Moradpour D, Haller O, Bartenschlager R. Interferon-alpha inhibits hepatitis C virus subgenomic RNA replication by an MxA-independent pathway. J Gen Virol. 2001;82:723-733. (Pubitemid 32280029)
21. Zhijian Y, Zhen H, Fan Z, Jin Y, Qiwen D, Zhongming Z. Hepatitis B virus core protein with hot-spot mutations inhibit MxA gene transcription but has no effect on inhibition of virus replication by interferon alpha. Virol J. 2010;7:278.
22. Roers A, Hochkeppel HK, Horisberger MA, Hovanessian A, Haller O. MxA gene expression after live virus vaccination: a sensitive marker for endogenous type I interferon. J Infect Dis. 1994;169:807-813. (Pubitemid 24102114)
23. Samuel CE. Antiviral actions of interferons. Clin Microbiol Rev. 2001;14:778-809. (Pubitemid 32979631)
24. Stetson DB, Medzhitov R. Type I interferons in host defense. Immunity. 2006;25:373-381. (Pubitemid 44354218)
25. Zhao C, Denison C, Huibregtse JM, Gygi S, Krug RM. Human ISG15 conjugation targets both IFN-induced and constitutively expressed proteins functioning in diverse cellular pathways. Proc Natl Acad Sci USA. 2005;102:10200-10205. (Pubitemid 41023349)
26. Malakhova OA, Yan M, Malakhov MP, et al. Protein ISGylation modulates the JAK-STAT signaling pathway. Genes Dev. 2003;17:455-460. (Pubitemid 36258760)
27. Lenschow DJ, Lai C, Frias-Staheli N, et al. IFN-stimulated gene 15 functions as a critical antiviral molecule against influenza, herpes, and Sindbis viruses. Proc Natl Acad Sci USA. 2007;104:1371-1376. (Pubitemid 46184011)
28. Lai C, Struckhoff JJ, Schneider J, et al. Mice lacking the ISG15 E1 enzyme UbE1L demonstrate increased susceptibility to both mouse-adapted and non-mouse-adapted influenza B virus infection. J Virol. 2009;83:1147-1151.
29. Chen L, Sun J, Meng L, Heathcote J, Edwards AM, McGilvray ID. ISG15, a ubiquitin-like interferon-stimulated gene, promotes hepatitis C virus production in vitro: implications for chronic infection and response to treatment. J Gen Virol. 2010;91:382-388.
30. McGilvray I, Feld JJ, Chen L, Pattullo V, Guindi M, Fischer S. Hepatic cell-specific gene expression better predicts HCV treatment outcome than IL28B genotype. Gastroenterology. 2012;142:1122-1131.